We monitored serum levels of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) before and during intravenously applied immunoglobulin (IVIG) therapy in 33 patients with chronic immune-mediated neuropathies and myopathies and 15 controls. Baseline MMP-2 and TIMP-2 serum levels were lower and MMP-9 and TIMP-1 serum levels higher in all patients compared to age-matched controls. Eight days after IVIG treatment, MMP-2, TIMP-2, and TIMP-1 serum levels increased, while MMP-9 serum levels decreased, indicating tissue repair. After 60 days, MMP-9 levels increased, MMP-2 approached normal levels, while TIMP-1 and TIMP-2 serum levels were below day 8 levels, indicating relapsing tissue damage. Comparing the MMP/TIMP results with the clinical courses, IVIG treatment tended to change MMP/TIMP levels in a way that paralleled clinical improvement and relapse. In sum, during a distinct time period, IVIG therapy seems to be able to modulate MMP-mediated tissue repair.

Keywords:
Intravenous immunoglobulins, Matrix metalloproteinases, Neuromuscular disorders, Tissue inhibitor of matrix metalloproteinases, Intravenously applied immunoglobulin therapy
1.
Baker AH, Edwards DR, Murphy G: Metalloproteinase inhibitors: biological action and therapeutic opportunities. J Cell Sci 2002;115:3719–3727.
2.
Carmeli E, Moas M, Reznick AZ, Coleman R: Matrix metalloproteinases and skeletal muscle: a brief review. Muscle Nerve 2004;29:191–197.
3.
Kugler A: Matrix metalloproteinases and their inhibitors. Anticancer Res 1999;19:1589–1592.
4.
Choi YC, Dalakas MC: Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 2000;54:65–71.
5.
Hartung HP, Kieseier BC: The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 2000;107:140–147.
6.
Kieseier BC, Schneider C, Clements JM, Gearing AJ, Gold R, Toyka KV, Hartung HP: Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain 2001;124:341–351.
7.
Schoser BGH, Blottner D, Stuerenburg HJ: Matrix metalloproteinases in inflammatory myopathies: enhanced immunoreactivity near atrophic myofibers. Acta Neurol Scand 2002;105:309–313.
8.
Demestre M, Wells GM, Miller KM, Smith KJ, Hughes RAC, Gearing AJ, Gregson NA: Characterisation of matrix metalloproteinases and the effects of a broad-spectrum inhibitor (BB-1101) in peripheral nerve regeneration. Neuroscience 2004;124:767–779.
9.
Dalakas MC: The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004;102:177–193.
10.
Wiles CM, Brown P, Chapel H, et al: Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosug Psychiatry 2002;72:440–448.
11.
Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K: Serum gelatinases B, TIMP-1 and TIMP-2 levels in multiple sclerosis. Brain 1999;122:191–197.
12.
Mirowska D, Wicha W, Czlonkowski A, Czlonkowska A, Weber F: Increase of matrix metalloproteinase-9 in peripheral blood of multiple sclerosis patients treated with high doses of methylprednisolone. J Neuroimmunol 2004;146:171–175.
13.
Sharshar T, Durand MC, Lefaucheur JP, Lofaso F, Raphael JC, Gherardi RK, Creange A: MMP-9 correlates with electrophysiological abnormalities in Guillain-Barré syndrome. Neurology 2002;59:1649–1651.
14.
Shapiro S, Shoenfeld Y, Gilburd B, Sobel E, Lahat N: Intravenous γ-globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 2002;95:2032–2037.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.